Compare VMAR & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VMAR | AZTR |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.5M |
| IPO Year | 2020 | 2023 |
| Metric | VMAR | AZTR |
|---|---|---|
| Price | $1.31 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 86.4K | ★ 580.8K |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $0.10 |
| 52 Week High | $8.88 | $1.40 |
| Indicator | VMAR | AZTR |
|---|---|---|
| Relative Strength Index (RSI) | 31.21 | 66.40 |
| Support Level | $1.17 | $0.26 |
| Resistance Level | $1.64 | $0.32 |
| Average True Range (ATR) | 0.15 | 0.01 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 23.81 | 86.79 |
Vision Marine Technologies Inc designs and manufactures electric outboard powertrain systems, power boats, related technology, and rents electric boats. Its models include Bruce 22, Fantail 217, VX Electric Pontoon, Volt 180, Phantom, and others. The company provides goods and services for the recreational boating market and focuses on electric outboard powertrain systems, electric power boats, and the renting of electric boats through its subsidiary. It sells boats, parts, and accessories and offers services related to recreational boating, including boats with internal combustion engines and electric propulsion. The company operates in two reportable segments, the sale of electric boats and the rental of electric boats, and generates a substantial portion of its revenue from the USA.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.